Other analysts also recently issued reports about the stock. HC Wainwright reaffirmed a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday. Argus upped their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH lifted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a report on Thursday, October 31st. The Goldman Sachs Group upped their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research note on Friday, November 1st. Finally, Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $388.25.
View Our Latest Report on United Therapeutics
United Therapeutics stock traded up $4.73 during trading hours on Thursday, hitting $323.62. 997,173 shares of the stock traded hands, compared to its average volume of 420,049. United Therapeutics has a one year low of $221.53 and a one year high of $417.82. The firm's 50-day moving average price is $360.44 and its two-hundred day moving average price is $360.55. The company has a market cap of $14.45 billion, a PE ratio of 14.21, a PEG ratio of 0.97 and a beta of 0.57.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the company posted $4.36 earnings per share. On average, sell-side analysts expect that United Therapeutics will post 24.48 earnings per share for the current fiscal year.
In other United Therapeutics news, Director Louis W. Sullivan sold 26,209 shares of the company's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares of the company's stock, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the business's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the sale, the executive vice president now directly owns 36,710 shares of the company's stock, valued at approximately $13,743,122.70. The trade was a 17.34 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,164 shares of company stock worth $45,278,893. Insiders own 11.90% of the company's stock.
A number of institutional investors have recently bought and sold shares of the stock. Wealthfront Advisers LLC increased its position in United Therapeutics by 2,090,573.5% in the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after buying an additional 18,313,424 shares in the last quarter. Vanguard Group Inc. increased its holdings in United Therapeutics by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock worth $1,567,253,000 after acquiring an additional 32,213 shares in the last quarter. FMR LLC raised its stake in United Therapeutics by 36.5% during the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after acquiring an additional 393,777 shares during the period. Geode Capital Management LLC lifted its holdings in United Therapeutics by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock valued at $401,184,000 after purchasing an additional 44,277 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of United Therapeutics by 0.8% in the fourth quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock worth $344,176,000 after purchasing an additional 7,710 shares during the period. 94.08% of the stock is owned by institutional investors.
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.